FDA
-
-
-
-
-
-
-
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
-
-
-
-
-
-
-
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
-
-
-
-
-
-
-
AB Science reports its revenues for the year 2024 and provides an update on its activities
-
-
-
-
-
-
-
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
-
-
-
-
-
-
-
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
-
-
-
-
-
-
-
AB Science reports its revenues for the year 2021 and provides an update on its activities
-
-
-
-
-
-
-
AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
-
322,203 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

